GlassScriptPhysician profile
Andrei N Dokukin
NPI 1770715575
$13,635.24
in general payments reported to CMS, 2019-2025
12 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $20.54 · 2021: $200 · 2022: $4,232 · 2023: $8,515 · 2024: $311 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $7,963 · Food and Beverage: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $7,962.96 |
| Food and Beverage | $1,066.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $12,422.35 | 2022-2023 | Zimhi, Lucemyra |
| Braeburn INC. | $363.35 | 2024-2025 | Brixadi |
| Alkermes, INC. | $234.53 | 2019-2024 | Vivitrol, Aristada, Vivitrol |
| Janssen Pharmaceuticals, INC | $155.16 | 2023 | Spravato |
| Boston Scientific Corporation | $116.25 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Novo Nordisk INC | $92.13 | 2021-2024 | Wegovy |
| Orexo US, INC. | $79.80 | 2019-2021 | |
| Lilly USA, LLC | $53.39 | 2021 | |
| Biodelivery Sciences International, INC. | $41.36 | 2021 | |
| Janssen Scientific Affairs, LLC | $27.72 | 2023 | Spravato |
| Forte Bio-Pharma LLC | $27.30 | 2019-2021 | |
| Radius Health, INC. | $21.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrei Dokukin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.